"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_department","contact_institute","contact_address","contact_city","contact_zip/postal_code","contact_country","supplementary_file","data_row_count"
"GSM820048","col001","GSM820048","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 41,6","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 2000","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL001.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820048/GSM820048.CEL.gz","54675"
"GSM820049","col002","GSM820049","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 66,06","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 140","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL002.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820049/GSM820049.CEL.gz","54675"
"GSM820050","col003","GSM820050","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 80,19","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 62","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL003.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820050/GSM820050.CEL.gz","54675"
"GSM820051","col004","GSM820051","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 87,36","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 832","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL004.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820051/GSM820051.CEL.gz","54675"
"GSM820052","col005","GSM820052","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 60,49","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1175","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL005.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820052/GSM820052.CEL.gz","54675"
"GSM820053","col006","GSM820053","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 76,55","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1541","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL006.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820053/GSM820053.CEL.gz","54675"
"GSM820054","col007","GSM820054","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 61,3","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1613","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL007.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820054/GSM820054.CEL.gz","54675"
"GSM820055","col008","GSM820055","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 82,16","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 748","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL008.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820055/GSM820055.CEL.gz","54675"
"GSM820056","col009","GSM820056","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 92,15","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1545","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL009.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820056/GSM820056.CEL.gz","54675"
"GSM820057","col010","GSM820057","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 54,56","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1175","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL010.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820057/GSM820057.CEL.gz","54675"
"GSM820058","col011","GSM820058","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 73,41","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 657","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL011.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820058/GSM820058.CEL.gz","54675"
"GSM820059","col012","GSM820059","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 55,15","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1137","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL012.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820059/GSM820059.CEL.gz","54675"
"GSM820060","col013","GSM820060","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 82,66","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 499","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL013.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820060/GSM820060.CEL.gz","54675"
"GSM820061","col014","GSM820061","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 84,4","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1470","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL014.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820061/GSM820061.CEL.gz","54675"
"GSM820062","col015","GSM820062","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 50,11","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1433","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL015.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820062/GSM820062.CEL.gz","54675"
"GSM820063","col016","GSM820063","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 47,7","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 2810","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL016.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820063/GSM820063.CEL.gz","54675"
"GSM820064","col017","GSM820064","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 64,9","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 2868","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL017.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820064/GSM820064.CEL.gz","54675"
"GSM820065","col018","GSM820065","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 75,49","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1774","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL018.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820065/GSM820065.CEL.gz","54675"
"GSM820066","col019","GSM820066","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 76,2","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1928","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL019.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820066/GSM820066.CEL.gz","54675"
"GSM820067","col020","GSM820067","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 65,7","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 1060","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL020.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820067/GSM820067.CEL.gz","54675"
"GSM820068","col021","GSM820068","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 86,41","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 929","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL021.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820068/GSM820068.CEL.gz","54675"
"GSM820069","col022","GSM820069","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 48","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 3550","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL022.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820069/GSM820069.CEL.gz","54675"
"GSM820070","col023","GSM820070","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: col01","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1329","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL023.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820070/GSM820070.CEL.gz","54675"
"GSM820071","col024","GSM820071","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 76,22","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 204","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL024.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820071/GSM820071.CEL.gz","54675"
"GSM820072","col026","GSM820072","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 60,11","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 357","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL026.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820072/GSM820072.CEL.gz","54675"
"GSM820073","col033","GSM820073","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 82,02","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 994","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL033.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820073/GSM820073.CEL.gz","54675"
"GSM820074","col034","GSM820074","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 79,05","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1413","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL034.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820074/GSM820074.CEL.gz","54675"
"GSM820075","col035","GSM820075","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 67,1","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 2157","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL035.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820075/GSM820075.CEL.gz","54675"
"GSM820076","col036","GSM820076","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 71,9","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1977","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL036.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820076/GSM820076.CEL.gz","54675"
"GSM820077","col037","GSM820077","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 64,62","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1807","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL037.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820077/GSM820077.CEL.gz","54675"
"GSM820078","col038","GSM820078","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 95,13","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 446","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL038.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820078/GSM820078.CEL.gz","54675"
"GSM820079","col039","GSM820079","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 71,83","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1859","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL039.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820079/GSM820079.CEL.gz","54675"
"GSM820080","col040","GSM820080","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 76,79","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 2273","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL040.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820080/GSM820080.CEL.gz","54675"
"GSM820081","col041","GSM820081","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 57,72","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1959","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL041.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820081/GSM820081.CEL.gz","54675"
"GSM820082","col044","GSM820082","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 78,27","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 1278","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL044.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820082/GSM820082.CEL.gz","54675"
"GSM820083","col045","GSM820083","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 75,35","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 269","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL045.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820083/GSM820083.CEL.gz","54675"
"GSM820084","col046","GSM820084","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 83,2","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 3555","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL046.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820084/GSM820084.CEL.gz","54675"
"GSM820085","col047","GSM820085","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 57,8","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 3599","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL047.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820085/GSM820085.CEL.gz","54675"
"GSM820086","col048","GSM820086","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 90,57","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 974","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL048.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820086/GSM820086.CEL.gz","54675"
"GSM820087","col049","GSM820087","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 94,56","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1473","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL049.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820087/GSM820087.CEL.gz","54675"
"GSM820088","col050","GSM820088","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 68,57","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 446","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL050.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820088/GSM820088.CEL.gz","54675"
"GSM820089","col051","GSM820089","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 75,91","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 236","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL051.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820089/GSM820089.CEL.gz","54675"
"GSM820090","col052","GSM820090","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 57,26","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 332","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL052.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820090/GSM820090.CEL.gz","54675"
"GSM820091","col053","GSM820091","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 54,07","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 437","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL053.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820091/GSM820091.CEL.gz","54675"
"GSM820092","col054","GSM820092","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 50,81","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 438","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL054.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820092/GSM820092.CEL.gz","54675"
"GSM820093","col055","GSM820093","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 78,78","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1006","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL055.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820093/GSM820093.CEL.gz","54675"
"GSM820094","col056","GSM820094","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 46,44","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 803","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL056.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820094/GSM820094.CEL.gz","54675"
"GSM820095","col057","GSM820095","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 74,6","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 2414","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL057.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820095/GSM820095.CEL.gz","54675"
"GSM820096","col058","GSM820096","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 68,91","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1174","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL058.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820096/GSM820096.CEL.gz","54675"
"GSM820097","col059","GSM820097","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 34,64","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 391","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL059.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820097/GSM820097.CEL.gz","54675"
"GSM820098","col060","GSM820098","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 79,3","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 3065","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL060.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820098/GSM820098.CEL.gz","54675"
"GSM820099","col061","GSM820099","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 78,09","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 474","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL061.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820099/GSM820099.CEL.gz","54675"
"GSM820100","col062","GSM820100","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 80,38","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 457","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL062.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820100/GSM820100.CEL.gz","54675"
"GSM820101","col063","GSM820101","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 80,57","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1260","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL063.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820101/GSM820101.CEL.gz","54675"
"GSM820102","col064","GSM820102","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 77,12","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 54","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL064.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820102/GSM820102.CEL.gz","54675"
"GSM820103","col065","GSM820103","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 63,5","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1983","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL065.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820103/GSM820103.CEL.gz","54675"
"GSM820104","col066","GSM820104","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 77,79","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1667","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL066.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820104/GSM820104.CEL.gz","54675"
"GSM820105","col067","GSM820105","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 57","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 2141","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL067.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820105/GSM820105.CEL.gz","54675"
"GSM820106","col068","GSM820106","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 74,06","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1281","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL068.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820106/GSM820106.CEL.gz","54675"
"GSM820107","col069","GSM820107","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 55,21","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 409","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL069.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820107/GSM820107.CEL.gz","54675"
"GSM820108","col070","GSM820108","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 75,72","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 56","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL070.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820108/GSM820108.CEL.gz","54675"
"GSM820109","col072","GSM820109","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 77,35","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1640","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL072.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820109/GSM820109.CEL.gz","54675"
"GSM820110","col073","GSM820110","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 80,75","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 971","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL073.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820110/GSM820110.CEL.gz","54675"
"GSM820111","col074","GSM820111","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 74,72","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1189","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL074.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820111/GSM820111.CEL.gz","54675"
"GSM820112","col075","GSM820112","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 76,57","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1184","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL075.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820112/GSM820112.CEL.gz","54675"
"GSM820113","col076","GSM820113","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 69,53","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1785","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL076.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820113/GSM820113.CEL.gz","54675"
"GSM820114","col077","GSM820114","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 63,07","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1837","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL077.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820114/GSM820114.CEL.gz","54675"
"GSM820115","col078","GSM820115","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 81,41","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1844","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL078.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820115/GSM820115.CEL.gz","54675"
"GSM820116","col079","GSM820116","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 72,46","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 273","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL079.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820116/GSM820116.CEL.gz","54675"
"GSM820117","col080","GSM820117","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 63,98","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 538","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL080.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820117/GSM820117.CEL.gz","54675"
"GSM820118","col081","GSM820118","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 88,03","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1608","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL081.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820118/GSM820118.CEL.gz","54675"
"GSM820119","col082","GSM820119","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 73,98","Sex: f","meta or recurrence within 3 years: yes","time to meta or recurrence: 634","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL082.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820119/GSM820119.CEL.gz","54675"
"GSM820120","col083","GSM820120","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 76,02","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 736","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL083.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820120/GSM820120.CEL.gz","54675"
"GSM820121","col084","GSM820121","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 66,91","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1378","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL084.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820121/GSM820121.CEL.gz","54675"
"GSM820122","col085","GSM820122","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 54,05","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1582","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL085.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820122/GSM820122.CEL.gz","54675"
"GSM820123","col086","GSM820123","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 63,89","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 447","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL086.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820123/GSM820123.CEL.gz","54675"
"GSM820124","col089","GSM820124","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 61,5","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1296","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL089.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820124/GSM820124.CEL.gz","54675"
"GSM820125","col090","GSM820125","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 86,06","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 893","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL090.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820125/GSM820125.CEL.gz","54675"
"GSM820126","col091","GSM820126","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 84,57","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1219","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL091.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820126/GSM820126.CEL.gz","54675"
"GSM820127","col092","GSM820127","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 85,98","Sex: m","meta or recurrence within 3 years: yes","time to meta or recurrence: 200","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL092.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820127/GSM820127.CEL.gz","54675"
"GSM820128","col093","GSM820128","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 71,26","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1319","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL093.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820128/GSM820128.CEL.gz","54675"
"GSM820129","col094","GSM820129","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 87,06","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 344","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL094.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820129/GSM820129.CEL.gz","54675"
"GSM820130","col095","GSM820130","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 52,5","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1230","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL095.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820130/GSM820130.CEL.gz","54675"
"GSM820131","col096","GSM820131","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 61,91","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1147","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL096.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820131/GSM820131.CEL.gz","54675"
"GSM820132","col097","GSM820132","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 61,76","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1042","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL097.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820132/GSM820132.CEL.gz","54675"
"GSM820133","col098","GSM820133","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 48,82","Sex: m","meta or recurrence within 3 years: no","time to meta or recurrence: 1094","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL098.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820133/GSM820133.CEL.gz","54675"
"GSM820134","col099","GSM820134","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 68,84","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1061","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL099.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820134/GSM820134.CEL.gz","54675"
"GSM820135","col100","GSM820135","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 81,42","Sex: f","meta or recurrence within 3 years: na","time to meta or recurrence: 50","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL100.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820135/GSM820135.CEL.gz","54675"
"GSM820136","col101","GSM820136","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 77,76","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1431","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL101.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820136/GSM820136.CEL.gz","54675"
"GSM820137","col102","GSM820137","Public on Nov 05 2011","Oct 20 2011","Mar 18 2013","RNA","1","Primary tumor resection","Homo sapiens","disease status: AJCC stage II CRC","tissue: primary tumor resection","age at diagnosis: 49,23","Sex: f","meta or recurrence within 3 years: no","time to meta or recurrence: 1428","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","COL102.CEL","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM820nnn/GSM820137/GSM820137.CEL.gz","54675"
"GSM1100477","Normal mucosa, sample 1","GSM1100477","Public on Mar 18 2013","Mar 18 2013","Apr 08 2013","RNA","1","Normal colon mucosa","Homo sapiens","disease status: AJCC stage II CRC","tissue: normal colon mucosa","matching tumor sample: col015","","","","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","col027","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1100nnn/GSM1100477/GSM1100477_COL_27.CEL.gz","33777"
"GSM1100478","Normal mucosa, sample 2","GSM1100478","Public on Mar 18 2013","Mar 18 2013","Apr 08 2013","RNA","1","Normal colon mucosa","Homo sapiens","disease status: AJCC stage II CRC","tissue: normal colon mucosa","matching tumor sample: col006","","","","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","col028","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1100nnn/GSM1100478/GSM1100478_COL_28.CEL.gz","33777"
"GSM1100479","Normal mucosa, sample 3","GSM1100479","Public on Mar 18 2013","Mar 18 2013","Apr 08 2013","RNA","1","Normal colon mucosa","Homo sapiens","disease status: AJCC stage II CRC","tissue: normal colon mucosa","","","","","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","col029","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1100nnn/GSM1100479/GSM1100479_COL_29.CEL.gz","33777"
"GSM1100480","Normal mucosa, sample 4","GSM1100480","Public on Mar 18 2013","Mar 18 2013","Apr 08 2013","RNA","1","Normal colon mucosa","Homo sapiens","disease status: AJCC stage II CRC","tissue: normal colon mucosa","","","","","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","col030","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1100nnn/GSM1100480/GSM1100480_COL_30.CEL.gz","33777"
"GSM1100481","Normal mucosa, sample 5","GSM1100481","Public on Mar 18 2013","Mar 18 2013","Apr 08 2013","RNA","1","Normal colon mucosa","Homo sapiens","disease status: AJCC stage II CRC","tissue: normal colon mucosa","matching tumor sample: col004","","","","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","col031","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1100nnn/GSM1100481/GSM1100481_COL_31.CEL.gz","33777"
"GSM1100482","Normal mucosa, sample 6","GSM1100482","Public on Mar 18 2013","Mar 18 2013","Apr 08 2013","RNA","1","Normal colon mucosa","Homo sapiens","disease status: AJCC stage II CRC","tissue: normal colon mucosa","matching tumor sample: col026","","","","total RNA","Total RNA was isolated using Trizol (Invitrogen) and purified with RNeasy (Qiagen) according to manufacturer’s protocol.","biotin","RNA sample integrity was checked on an Agilent 2100 Bioanalyzer (Agilent Technologies). 4 µg of total RNA was used for cRNA synthesis and fragmented. Labeling was performed with One-Cycle cDNA synthesis Kit (Affymetrix) according to manufacturer’s protocol. Sample quality was checked on a Bioanalyzer prior and after fragmentation.","9606","10 µg of labeled cRNA was hybridized to Affymetrix Human genome U133 Plus 2.0 arrays according to manufacturer’s protocol (Affymetrix).","Arrays were scanned with a GeneChip Scanner 3000 (Affymetrix) according to manufacturer’s protocol","col032","Expression data (cel files) were normalized with the MAS5.0 algorithm (target signal = 100) using GCOS software (Affymetrix)","GPL570","Rogier,,Versteeg","r.versteeg@amc.uva.nl","Department of Human Genetics","Academic Medical Centre, University of Amsterdam","P.O. Box 22700","Amsterdam","1100DE","Netherlands","ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM1100nnn/GSM1100482/GSM1100482_COL_32.CEL.gz","33777"
